Table 3. Multivariate analysis for overall survival.
Full model | Reduced model without CRP | Reduced model with CRP | |||||||
---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | Bootstrap-corrected 95% CI | P | HR | Bootstrap-corrected 95% CI | P | |
Gender: male | 0.865 | 0.603–1.241 | 0.430 | ||||||
Age | 1.023 | 1.005–1.041 | <0.001 | 1.018 | 1.002–1.034 | 0.010 | 1.021 | 1.004–1.037 | 0.004 |
Poor performance status | |||||||||
(ECOG PS⩾2) | 2.038 | 1.350–3.080 | <0.001 | 3.387 | 2.283–5.272 | <0.001 | 2.368 | 1.526–3.943 | <0.001 |
Log (WBC) | 1.189 | 0.7832–1.8061 | 0.415 | ||||||
Haemoglobin<10 g dl−1 | 1.519 | 1.002–2.301 | 0.049 | 1.709 | 1.153–2.613 | 0.005 | 1.534 | 0.928–2.518 | 0.020 |
Creatinine | 1.036 | 0.935–1.148 | 0.500 | ||||||
Albumin: <3 g dl−1 | 0.863 | 0.532–1.400 | 0.550 | ||||||
Log (CRP) | 1.600 | 1.190–2.150 | <0.001 | 1.686 | 1.267–2.293 | <0.001 | |||
Log (ALP) | 1.281 | 0.659–2.490 | 0.465 | ||||||
Log (LDH) | 2.340 | 1.175–4.662 | 0.016 | 2.860 | 1.310–6.472 | 0.002 | 2.088 | 0.879–5.413 | 0.044 |
Visceral metastasis | 1.362 | 0.955–1.943 | 0.018 | 1.601 | 1.125–2.385 | 0.005 | 1.394 | 0.955–2.088 | 0.012 |
Hydronephrosis | 1.100 | 0.758–1.565 | 0.644 | ||||||
Primary organ | 0.187 | ||||||||
Upper urinary tract | 0.800 | 0.569–1.117 | |||||||
Corrected calcium | 1.158 | 0.898–1.493 | 0.259 | ||||||
Lymph node metastasis | 0.621 | 0.437–0.884 | 0.008 | 0.677 | 0.465–0.998 | 0.023 | 0.603 | 0.399–0.916 | 0.004 |
Prior definitive therapy | 1.034 | 0.691–1.546 | 0.872 | ||||||
Concordance index (original) | (95% CI) | 0.765 (0.739–0.792) | 0.788 (0.764–0.812) | ||||||
Concordance index (BOC) | 0.761 | 0.781 |
Abbreviations: ALP=alkaline phosphatase; BOC=Bootstrap optimism corrected; CRP=C-reactive protein; CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group Performance Status; HR=hazard ratio; LDH=lactate dehydrogenase; WBC=white blood cell.